Mitomycin Gel or Nephroureterectomy for Low-Grade Upper Tract Disease
A man with low-grade upper tract cancer in his only kidney faces a choice where nephroureterectomy means dialysis, not just reduced function — testing what a trial's real complication rate should weigh against an alternative that isn't abstract.
A.O., a 72-year-old man, has kept bees as a hobby for almost twenty years, tending eight hives on a half-acre behind his house and selling honey at the farmers market most Saturdays through the summer, work that requires steady footing on uneven ground and enough stamina to lift full supers without help. Fifteen years ago he underwent a left nephrectomy for a benign renal mass that turned out, on final pathology, not to require it in retrospect — a fact he brings up with some frustration whenever kidney function comes up in conversation, since it means the reserve he's living on today was reduced by a surgery his own tissue diagnosis later argued was unnecessary. Recent hematuria led to a diagnostic ureteroscopy that found a 1.2cm papillary lesion in his right renal pelvis, biopsy-confirmed low-grade urothelial carcinoma, in what is now his only kidney, with a current eGFR of 51 that leaves little room to absorb further loss.
The standard treatment for upper tract urothelial carcinoma has traditionally been nephroureterectomy, but A.O.'s solitary kidney status changes the stakes of that recommendation considerably — a nephroureterectomy here means dialysis, not just a reduction in renal reserve, since there is no second kidney left to compensate. UGN-101, a mitomycin-containing reverse-thermal gel delivered directly into the renal pelvis, offers a kidney-sparing alternative: the pivotal OLYMPUS trial achieved a fifty-nine percent complete response rate in patients with low-grade upper tract disease, and longer-term follow-up found a median duration of response approaching four years in those who responded, durability that reads as a genuine long-term alternative rather than a brief reprieve. But the same trial reported ureteral stenosis in forty-four percent of treated patients — a real, common complication, not a rare tail risk, and one that in a solitary kidney carries its own obstruction and functional consequences, since a stenosed and obstructed sole kidney is its own path toward the same dialysis outcome chemoablation was chosen specifically to avoid.
In clinic, weighing a solitary kidney's real stakes
In a patient with two kidneys, I'd have an easier time recommending nephroureterectomy outright — it's curative, definitive, and doesn't depend on an induction course working. Here, with his solitary kidney, the calculus obviously shifts, but I still want to name what chemoablation costs even when it works: OLYMPUS reported ureteral stenosis in forty-four percent of treated patients. That's not a rare complication we're weighing against a small inconvenience — it's close to half the trial's own population, and stenosis in a solitary kidney can mean obstruction with real functional consequences of its own.
I'd start with UGN-101 given his solitary kidney, precisely because the alternative is dialysis, not a reduction in function. Fifty-nine percent achieved a complete response in OLYMPUS, and the longer-term follow-up found a median duration of response approaching four years in those who responded — that's not a brief remission, that's real, durable disease control for a meaningful fraction of patients. A forty-four percent stenosis rate is real, but stenosis is a manageable complication — stenting, balloon dilation — compared to the alternative of starting dialysis at seventy-two.
If he had two working kidneys, I'd weight this differently. The whole argument for accepting chemoablation's real complication profile depends on what the alternative actually costs him, which in his case is his only kidney.
I think you're both circling the actual question without quite naming it directly: what would nephroureterectomy really cost HIM, specifically, given his current eGFR of 51 and no compensatory hypertrophy left to draw on? That's a more precise question than 'nephroureterectomy versus chemoablation' in the abstract. A man starting from an eGFR of 51 in a solitary kidney is not a hypothetical dialysis risk — nephrectomy of his only functioning kidney means dialysis, full stop, not a probabilistic decline.
Given that, I think the endourologist's framing is right for him specifically, not just as a general preference for nephron-sparing approaches: the fifty-nine percent response rate, with real four-year durability in responders, is a genuine chance at avoiding an unconditional dialysis outcome, and the forty-four percent stenosis risk, while real, is a complication with several management options rather than an irreversible endpoint. I'd want a nephrology consult before proceeding, specifically to characterize how much reserve he actually has to work with if chemoablation fails and nephroureterectomy becomes unavoidable later.
A.O. proceeded with UGN-101 induction after a nephrology consult confirmed his renal reserve could tolerate close monitoring during treatment, with a low threshold for stenting at the first sign of obstructive symptoms or hydronephrosis on surveillance imaging.
Not agreed: how many chemoablation cycles or how long a period of non-response should elapse before the team commits to nephroureterectomy and dialysis rather than continuing to pursue kidney preservation. The urologic oncologist wants a firm, pre-specified failure threshold set now, before treatment starts; the endourologist prefers to reassess after the first response evaluation, arguing a rigid pre-set threshold risks abandoning a kidney-sparing attempt too early.